Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Coxibs and cardiovascular risk.

× No keyword cloud information.

9 in total

1. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.

Authors: M Ouellet; D Riendeau; M D Percival
Journal: Proc Natl Acad Sci U S A Date: 2001-11-20 Impact factor: 11.205

2. COX-2 inhibitors and type 4 error.

Authors: Michal R Pijak; Frantisek Gazdik
Journal: CMAJ Date: 2003-08-05 Impact factor: 8.262

3. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

Authors: Scott D Solomon; John J V McMurray; Marc A Pfeffer; Janet Wittes; Robert Fowler; Peter Finn; William F Anderson; Ann Zauber; Ernest Hawk; Monica Bertagnolli
Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245

4. New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra).

Authors: Jill Cotter; Eric Wooltorton
Journal: CMAJ Date: 2005-04-15 Impact factor: 8.262

5. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.

Authors: Linda E Lévesque; James M Brophy; Bin Zhang
Journal: Ann Intern Med Date: 2005-04-05 Impact factor: 25.391

6. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors: F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal: JAMA Date: 2000-09-13 Impact factor: 56.272

Coxibs and cardiovascular risk.

1. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.

2. COX-2 inhibitors and type 4 error.

3. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

4. New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra).

5. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.

6. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

7. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.

8. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.

9. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.